Carrimycin in Patients With Locally Advanced, Recurrent, or Metastatic HNSCC (Non NPC): A Phase I Trial

PHASE1CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

December 20, 2019

Primary Completion Date

December 30, 2022

Study Completion Date

December 30, 2022

Conditions
Oral Squamous Cell CarcinomaHead and Neck Squamous Cell Carcinoma
Interventions
DRUG

Carrimycin

The study involves three dose groups: 200mg, 400mg and 600mg. Three patients are planned for each dose group. Starting from the low dose group, the treatment to three patients in the 200mg dose group: 200mg of Carrimycin after meals every morning (po) for three weeks, and then discontinue for one week, the tolerance and efficacy evaluation will be performed after the 4 weeks. DLT will be recorded during the 4 weeks.

Trial Locations (1)

200011

Ninth People's Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai

All Listed Sponsors
lead

Shanghai Jiao Tong University School of Medicine

OTHER

NCT04413214 - Carrimycin in Patients With Locally Advanced, Recurrent, or Metastatic HNSCC (Non NPC): A Phase I Trial | Biotech Hunter | Biotech Hunter